Vistagen Therapeutics (VTGN) Interest & Investment Income (2023 - 2026)

Vistagen Therapeutics has disclosed Interest & Investment Income across 4 years of filings, most recently posting $319000.0 for Q2 2026.

• In Q2 2026, Interest & Investment Income fell 55.13% year-over-year to $319000.0; the TTM figure through Jun 2026 stood at $2.0 million (down 47.08% YoY), while the FY2026 annual figure was $2.4 million, down 46.43% from the prior year.
• Interest & Investment Income came in at $319000.0 for Q2 2026 at Vistagen Therapeutics, down from $452000.0 in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $1.5 million in Q4 2023 to a low of $98000.0 in Q2 2023.
• Average Interest & Investment Income over 4 years is $820538.5, with a median of $711000.0 recorded in 2025.
• Year-over-year, Interest & Investment Income surged 1326.53% in 2024 and sank 55.13% in 2026.
• Over 4 years, Interest & Investment Income stood at $1.5 million in 2023, then tumbled by 32.79% to $1.0 million in 2024, then slumped by 37.25% to $647000.0 in 2025, then sank by 50.7% to $319000.0 in 2026.
• Per Business Quant data, the three most recent Interest & Investment Income figures were $319000.0 in Q2 2026, $452000.0 in Q1 2026, and $647000.0 in Q4 2025.